| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:CCI-007
CAS:939228-52-1
Purity:98% Package:25mg Remarks:S23517
|
| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:CCI-007
CAS:939228-52-1
Purity:>98 Package:1g,5g,10g,25g根据客户需要分装 Remarks:2g
|
|
| | CCI 007) Basic information |
| Product Name: | CCI 007) | | Synonyms: | CCI 007);CCI-007
(CCI00;Ethyl 2-(4-((2-amino-4-oxothiazol-5(4H)-ylidene)methyl)-2-methoxyphenoxy)acetate;CCI 007,MLL-r,CALM-AF10,HOXA9,MEIS1,Apoptosis,CMYC,CCI-007,SET-NUP214,inhibit,Inhibitor,CCI007;Acetic acid, 2-[4-[(2-amino-4-oxo-5(4H)-thiazolylidene)methyl]-2-methoxyphenoxy]-, ethyl ester;CCI-007, 10 mM in DMSO | | CAS: | 939228-52-1 | | MF: | C15H16N2O5S | | MW: | 336.36 | | EINECS: | | | Product Categories: | | | Mol File: | 939228-52-1.mol |  |
| | CCI 007) Chemical Properties |
| Boiling point | 515.2±60.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO: 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 80°C) | | pka | -2.32±0.20(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | CCI 007) Usage And Synthesis |
| Uses | CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells[1]. | | Biological Activity | CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells[1].
CCI-007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia[1].Following CCI-007 treatment for 24h, significant mitochondrial depolarization was observed in PER-485 cells as evidenced by a shift in JC-1 signal[1].Resistance to CCI-007 can occur by upregulation of MLL target gene expression[1].CCI-007 reverts the aberrant elevated transcription of disease-driving factors HOXA9, MEIS1, and CMYC downstream of the pathogenic MLL fusion protein, thereby inducing MLL-r leukemia cell death[2]. Cell Viability Assay[1] Cell Line: PER-485, MOLM-13, MV4;11 cells. | | References | [1]. Klaartje Somers, et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget. 2016 Jul 19;7(29):46067-46087.
[2]. Klaartje Somers, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene. 2019 May;38(20):3824-3842. |
| | CCI 007) Preparation Products And Raw materials |
|